Literature DB >> 17159085

Association of adrenal steroids with hypertension and the metabolic syndrome in blacks.

Srividya Kidambi1, Jane M Kotchen, Clarence E Grim, Hershel Raff, Jingnan Mao, Ravinder J Singh, Theodore A Kotchen.   

Abstract

Blacks have a high prevalence of hypertension and adrenal cortical adenomas/hyperplasia. We evaluated the hypothesis that adrenal steroids are associated with hypertension and the metabolic syndrome in blacks. Ambulatory blood pressures, anthropometric measurements, and measurements of plasma renin activity (PRA), aldosterone, fasting lipids, glucose, and insulin were obtained in 397 subjects (46% hypertensive and 50% female) after discontinuing antihypertensive and lipid-lowering medications. Hypertension was defined as average ambulatory blood pressure >130/85 mm Hg. Late-night and early morning salivary cortisol, 24-hour urine-free cortisol, and cortisone excretion were measured in a consecutive subsample of 97 subjects (40% hypertensive and 52% female). Compared with normotensive subjects, hypertensive subjects had greater waist circumference and unfavorable lipid profiles, were more insulin resistant, and had lower PRA and higher plasma aldosterone and both late-night and early morning salivary cortisol concentrations. Twenty-four-hour urine-free cortisol and cortisone did not differ. Overall, ambulatory blood pressure was positively correlated with plasma aldosterone (r=0.22; P<0.0001) and late-night salivary cortisol (r=0.23; P=0.03) and inversely correlated with PRA (r=-0.21; P<0.001). Plasma aldosterone correlated significantly with waist circumference, total cholesterol, triglycerides, insulin, and the insulin-resistance index. Based on Adult Treatment Panel III criteria, 17% of all of the subjects were classified as having the metabolic syndrome. Plasma aldosterone levels, but not PRA, were elevated in subjects with the metabolic syndrome (P=0.0002). The association of aldosterone with blood pressure, waist circumference, and insulin resistance suggests that aldosterone may contribute to obesity-related hypertension in blacks. In addition, we speculate that relatively high aldosterone and low PRA in these hypertensive individuals may reflect a mild variant of primary aldosteronism.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17159085     DOI: 10.1161/01.HYP.0000253258.36141.c7

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  80 in total

1.  Circulating aldosterone and natriuretic peptides in the general community: relationship to cardiorenal and metabolic disease.

Authors:  Alessia Buglioni; Valentina Cannone; Alessandro Cataliotti; S Jeson Sangaralingham; Denise M Heublein; Christopher G Scott; Kent R Bailey; Richard J Rodeheffer; Paolo Dessì-Fulgheri; Riccardo Sarzani; John C Burnett
Journal:  Hypertension       Date:  2014-11-03       Impact factor: 10.190

Review 2.  Activation of the aldosterone/mineralocorticoid receptor system in chronic kidney disease and metabolic syndrome.

Authors:  Miki Nagase
Journal:  Clin Exp Nephrol       Date:  2010-06-09       Impact factor: 2.801

Review 3.  Novel therapeutic targets for hypertension.

Authors:  Ludovit Paulis; Thomas Unger
Journal:  Nat Rev Cardiol       Date:  2010-06-22       Impact factor: 32.419

4.  Na+-sensitive elevation in blood pressure is ENaC independent in diet-induced obesity and insulin resistance.

Authors:  Jonathan M Nizar; Wuxing Dong; Robert B McClellan; Mariana Labarca; Yuehan Zhou; Jared Wong; Donald G Goens; Mingming Zhao; Nona Velarde; Daniel Bernstein; Michael Pellizzon; Lisa M Satlin; Vivek Bhalla
Journal:  Am J Physiol Renal Physiol       Date:  2016-02-03

Review 5.  The role of aldosterone in cardiovascular disease in people with diabetes and hypertension: an update.

Authors:  Guido Lastra-Gonzalez; Camila Manrique-Acevedo; James R Sowers
Journal:  Curr Diab Rep       Date:  2008-06       Impact factor: 4.810

Review 6.  Role of Mineralocorticoid Receptors in Obstructive Sleep Apnea and Metabolic Syndrome.

Authors:  Badhma Valaiyapathi; David A Calhoun
Journal:  Curr Hypertens Rep       Date:  2018-03-19       Impact factor: 5.369

Review 7.  Kidney and epigenetic mechanisms of salt-sensitive hypertension.

Authors:  Wakako Kawarazaki; Toshiro Fujita
Journal:  Nat Rev Nephrol       Date:  2021-02-24       Impact factor: 28.314

Review 8.  The necessity and effectiveness of mineralocorticoid receptor antagonist in the treatment of diabetic nephropathy.

Authors:  Atsuhisa Sato
Journal:  Hypertens Res       Date:  2015-03-12       Impact factor: 3.872

Review 9.  Interaction of aldosterone and extracellular volume in the pathogenesis of obesity-associated kidney disease: a narrative review.

Authors:  Andrew S Bomback; Philip J Klemmer
Journal:  Am J Nephrol       Date:  2009-03-20       Impact factor: 3.754

10.  Serum Cortisol-to-Cortisone Ratio and Blood Pressure in Severe Obesity before and after Weight Loss.

Authors:  James B Byrd; Amy E Rothberg; Robert Chomic; Charles F Burant; Robert D Brook; Richard J Auchus
Journal:  Cardiorenal Med       Date:  2015-09-09       Impact factor: 2.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.